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Statement of translational relevance 
Radiation pneumonitis is a dose limiting toxicity of thoracic radiation therapy. 
Combining patient factors like hypertension, the lung dosimetric parameters 
like mean lung dose, and plasma levels of biomarkers like IL-8 and CCL2, this 
study built and validated internally a predictive model for radiation pneumonitis 
grade≥2 with AUC of 0.863 and accuracy 80% in patients with non-small-cell 
lung cancer who underwent radiation therapy. Should these be validated by an 
external database, this study will provide an opportunity to guide clinicians for 
personalized radiation dose prescription in future trials or clinical practice, to 
improve patient’s survival while limiting the risk of radiation pneumonitis. 
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Abstract 
Purpose 
Radiation pneumonitis is an important adverse event in patients with 
non-small-cell lung cancer (NSCLC) receiving thoracic radiation therapy (RT). 
However, the risk of radiation pneumonitis grade≥2 (RP2) has not been well 
predicted. This study hypothesized that inflammatory cytokines or the dynamic 
changes during-RT can improve predictive accuracy for RP2.  
Materials and Methods 
Levels of 30 inflammatory cytokines and clinical information in patients with 
stages I-III NSCLC treated with RT were from our prospective studies. 
Statistical analysis was used to select predictive cytokine candidates and 
clinical covariates for adjustment. Machine learning algorithm was used to 
develop the generalized linear model for predicting risk RP2. 
Results 
A total of 131 patients were eligible, 17 (13.0%) developed RP2. IL-8 and 
CCL2 had significantly (Bonferroni) lower expression levels in patients with 
RP2 than without RP2. But none of the changes in cytokine levels during RT 
was significantly associated with RP2. The final predictive GLM model for RP2 
was established including IL-8 and CCL2 at baseline level and two clinical 
variables. Nomogram was constructed based on the GLM model. The model’s 
predicting ability was validated in the completely independent test-set (area 
under curve=0.863, accuracy=80.0%, sensitivity=100%, specificity=76.5%). 
Conclusion 
By machine learning, this study has developed and validated a comprehensive 
model integrating inflammatory cytokines with clinical variables to predict RP2 
before RT which provides an opportunity to guide clinicians.    
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Introduction 1 
Radiation therapy (RT) plays an important role in the treatment of lung cancer, 2 
the leading cause of cancer death. Radiation induced lung toxicity (RILT) is a 3 
common and dose limiting adverse effect of thoracic RT in lung cancer 4 
patients, which may decrease quality of life, lead to pulmonary failure, and 5 
become life-threatening.1,2 Radiation pneumonitis (RP), one of the commonly 6 
reported RILT, usually occurs within 1 to 6 months after completion of RT.3 In 7 
patients treated with concurrent chemoradiation therapy,4-6 7.0 to 32.0% of 8 
patients have grade 2 and above (RP2) while 2.6 to 18.0% with severe RP 9 
Grade ≥3.  10 
 11 
We and others have previously demonstrated that the risk of RILT is 12 
correlated with radiation dosimetric factors, like mean lung dose (MLD)2,7,8 13 
with AUC<0.60. Proteomic analysis demonstrated that molecules associated 14 
with inflammation pathways such as C4b-binding protein alpha chain 15 
(C4BPA), Complement C3 (C3) and vitronectin (VTN) had substantially 16 
higher expression levels in patients with grade≥ 2 RILT.9 Addition of 17 
C4BPA+VTN to MLD improved the RILT predictive accuracy (AUC=0.71).10 18 
We also found radiation-induced elevation in plasma TGF-β1 level during RT 19 
had predictive ability of RILT.11 TGF-β1 combined with MLD stratified patients 20 
for high risk of RILT.12 Additionally, we demonstrated that combining IL-8, 21 
TGF-β1, and MLD into a single model yielded a good predictive ability 22 
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(AUC=0.80).8 In addition, baseline pulmonary function, including FEV1, FVC, 23 
and DLCO, may be related to the risk of RILT2.13  24 
 25 
The pathogenesis of RILT is described as multiple inter-reacting cellular 26 
activities such as hypoxia, fibrogenesis, inflammation, and angiogenesis.14 It 27 
is known that RILT combined the events of RP and radiation induced lung 28 
fibrosis (RILF) together, though RP and RILF have different 29 
biopathophysiological mechanisms. RP is associated with inflammatory 30 
reaction, while the latter is direct results of fibrosis and scar formation. The 31 
biomarkers of RP have been studied more extensively for clinical prediction. 32 
Kim JY, et al.15 found that TGF-β1 level became significantly higher at 4 33 
weeks after RT (p = 0.007). Variations of circulating IL-1A, IL-6, and IL-10 34 
were also significant with RP (p<0.05).16,17 Serum superoxide dismutase 35 
(SOD) has the predictive ability of RP with a sensitivity of about 0.8, and a 36 
specificity of about 0.7.18,19 Additionally, some groups revealed a number of 37 
single-nucleotide polymorphism markers (SNPs)20-23 were significantly 38 
correlated with the incidence of RP, including TGF-β1 rs1982073 with RP2 39 
(hazard ratio = 0.489);20 TGF-β1 rs11466345 with RP3 (hazard ratio = 40 
2.295).21 Genetic variation in the pro-inflammatory genes IL-1A, IL-8, TNF, 41 
TNFRSF1B, and MIF also significantly increased the risk of RP;22 MTHFR 42 
rs1801131 with RP2 (hazard ratio = 0.37).23 These studies suggested that 43 
individual patient’s genetic makeup and cytokine milieu may play critical roles 44 
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in an individual’s response to RP2 development. However, no study to date 45 
has reported good validated models to predict the risk of RP. 46 
 47 
In this study, we hypothesized that cytokines may play a vital role in predicting 48 
RP. We measured the plasma levels of representative cytokines of having 49 
immunomodulating and inflammatory effects, including interleukin, colony 50 
stimulating factor, interferon, tumor necrosis factor, transforming growth factor, 51 
growth factor and chemokine families, and even their changing dynamic 52 
during the course of radiation. This study aimed to build and validate a model 53 
to predict RP2 by using plasma cytokine in patients with NSCLC who 54 
underwent radiation therapy.  55 
 56 
Materials and Methods 57 
Study population 58 
Eligible subjects included patients with stages I-III NSCLC undergoing 59 
radiation alone or combined radiation with chemotherapy (UMCC 2003.073, 60 
UMCC 2003.076, NCT00603057, NCT01190527). Patients with a life 61 
expectancy of less than 6 months were excluded as they might not benefit 62 
from local radiation and might not be assessable for late lung toxicity. No 63 
restrictions were placed on either the degree of weight loss or pulmonary 64 
compromise, or oxygen dependency. All clinical data, including clinical 65 
parameters, grading of RP, and blood samples, were prospectively collected. 66 
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 67 
Radiation therapy  68 
All patients received daily fractionated 3D conformal external beam 69 
radiotherapy technique with or without sequential or concurrent 70 
chemotherapy. No patients treated with stereotactic body RT were included in 71 
the analysis.3 In general, the radiation dose prescription is limited by MLD of 72 
20 Gy or normal lung tissue complication probability of 15%-17.5%. The lung 73 
dosimetric factors were computed with subtraction of gross tumor volume 74 
(GTV) overlapping with normal lung.  75 
 76 
Cytokines measurement 77 
A total 30 inflammation modulating cytokines were measured, including: EGF, 78 
VEGF, CCL2, CCL3, CCL4, CCL11, CX3CL1, CXCL10, G-CSF, GM-CSF, 79 
IFN-γ, TNF-α, IL-1a, IL-1b, IL-1r, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, 80 
IL-12p40, IL-12p70, IL-13, IL-15, IL-17, sCD40l, TGF-α, and TGF-β1. 81 
Cytokine measurements were performed in plasma samples at 3 time-points: 82 
at baseline (within 2 weeks before the start of RT) and at 2 and 4 weeks 83 
during RT. Cytokines were measured in pg/mL as previously described.24,25  84 
 85 
Evaluation of radiation pneumonitis 86 
The primary endpoint of radiation therapy was RP2, defined as RP grade≥2. 87 
RP was diagnosed and graded based on a modified criteria combining 88 
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RTOG/SWOG/CTCAE. The detailed grading definitions were previously 89 
described in our previous publications,2,12 consistent with a recent update 90 
from the expert panel of an AAPM task (Supplementary Table S1).26 91 
 92 
Statistical analysis 93 
Patients with detectable levels of all 30 cytokines were eligible. Chi-square 94 
test, Fisher’s exact test, and logistic regression were applied for univariate 95 
clinical variables’ analyses, in order to select covariates available for model 96 
development. GLMM (generalized linear mixed model) with Bonferroni 97 
multiplicity correction was used to assess the potential importance of each 98 
cytokine as well as its dynamics (at baseline, 2 and 4 weeks during-RT), after 99 
adjusting for potential prognostic covariates as identified in the univariate 100 
clinical variables’ analyses. Machine learning algorithm was used for 101 
developing the final prediction GLM (generalized linear model) model of risk 102 
RP2 based on selected cytokines and clinical covariates, as described in the 103 
next section. The nomogram was built based on the GLM model for risk RP2. 104 
ROC curves and its corresponding AUC value, accuracy, sensitivity, 105 
specificity, positive predictive value (PPV) and negative predictive value (NPV) 106 
were calculated to show the performance of the GLM model. All analyses 107 
were performed after data normalization: Log-transformed all cytokine levels 108 
and GTV. All statistical tests were 2-sided, and the overall adjusted p-value 109 
threshold was 0.05. All analyses were performed using the "R" version 110 
Association for Cancer Research. 
 by guest on August 24, 2020. Copyright 2019 Americanhttps://bloodcancerdiscov.aacrjournals.orgDownloaded from 
9 
 
3.3.2.27 111 
 112 
Machine learning 113 
Given the concern about generalization performance, machine learning was 114 
adopted here to build the generalized linear model (GLM). The methodology 115 
of the process can be divided into the following steps. 1) Divide the dataset 116 
into a training cross-validation set (trainCV-set) and a test-set (80% and 20%). 117 
2) Use ten times 10-fold cross-validation (CV) in the trainCV-set to avoid 118 
over-fitting. In the progress of CV, the trainCV-set was divided into training-set 119 
and CV-set (9 folds and 1 fold); the most fitted GLM model was generated on 120 
training-set by model performance criteria AIC; and the mean standard error 121 
(MSE) of the GLM model was calculated on the CV-set. 3) Select the model, 122 
which had an MSE value closest to the mean MSE value, as the final model 123 
for predicting RP2. 4) Tested the final GLM model in test-set, which is unused 124 
and is completely independent with the trainCV-set. Given the imbalanced 125 
data (17 cases with RP2), we random resample those datasets carefully in 126 
keeping the ratio of RP2 not to zero.   127 
 128 
Results 129 
Patients Characteristics and RP2 130 
A total of 131 consecutive patients with NSCLC met the study criteria. Median 131 
age was 65.7 years (range 59.4-73.9), 22.9% were female. 84.7% were 132 
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treated with a combination of chemotherapy and RT. Seventeen of 131 133 
patients (13.0%) developed RP2 at a minimum follow-up of 12 months.  134 
 135 
Table 1 shows the clinical variables included in this study, including gender, 136 
age, Karnofsky performance status (KPS), smoking history, Chronic 137 
obstructive pulmonary disease (COPD), Cardiovascular disease (CVD), 138 
Hypertension, tumor location, tumor clinical stage, gross tumor volume (GTV), 139 
whether received chemotherapy, mean lung dose (MLD), mean heart dose 140 
(MHD), and equivalent dose in 2Gy fraction (EQD2). Under univariate 141 
analysis, MLD was significantly correlated with the risk of RP2 (p-value= 142 
0.029). Three candidate clinical variables with p-value<0.1, including MLD, 143 
Hypertension, and GTV were selected as covariates for further multivariable 144 
analysis. 145 
 146 
Analysis of single cytokine with RP2 147 
To identify the most influential inflammatory cytokines in predicting RP2, the 148 
associations between the risk of RP2 and cytokine expression level and rate 149 
of level change were analyzed using GLMM models. Time points (baseline, 2 150 
and 4 weeks during RT) were defined as random effects in GLMM model. The 151 
suitable GLMM model for every single cytokine, adjusted by the three 152 
selected clinical variables (Hypertension, GTV, and MLD), was determined by 153 
the minimum AIC score. Analysis showed that two cytokines (IL-8 and CCL2) 154 
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had significantly (p-value < 0.0017, Bonferroni) lower expression levels in 155 
patients with RP2 than those without RP2 (Figure 1 and Table 2). However, 156 
none of the temporal rate of cytokine’s level during RT was statistically 157 
significant for risk RP2 after multiplicity adjustment. The full data was supplied 158 
in Supplementary Table S2. 159 
 160 
Multivariable model for predicting RP2 161 
Based on the above analysis, the expression levels of IL-8 and CCL2 at 162 
baseline as possible early predictors of RP2, along with the three clinical 163 
variables (Hypertension, GTV, and MLD), might be the candidates for the final 164 
multivariable GLM models for predicting the risk of RP2. To guarantee the 165 
predictors following a normal distribution and orthogonality, their distributions 166 
(IL-8, CCL2, and GTV in log transform) and correlations were shown in Figure 167 
2. It can be seen that there were no strong correlations among them, while a 168 
straightforward relationship between MLD and GTV was found. According to 169 
their p-values (Table 1) and further clinical usage of the model, MLD was 170 
retained as one predictive candidate in the final multivariable model.  171 
 172 
The final multivariable logistic prediction model was generated by machine 173 
learning as described above. This included two cytokines (IL-8 and CCL2) 174 
and two clinical variables (Hypertension and MLD), as shown in Table 2. The 175 
nomogram for predicting risk RP2 was constructed using the GLM model, as 176 
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shown in Figure 3. To evaluate the final model’s generalization performance, 177 
this model was validated in test-set which was completely independent with 178 
trainCV-set. The predictive performances on test-set were the following: 179 
AUC=0.863 (95%CI=0.676~1, p-value=0.027), accuracy=80.0%, 180 
sensitivity=100%, specificity=76.5%, PPV=42.9%, NPV=100%. On the full 181 
dataset, the final GLM model had classified performances as the following: 182 
AUC=0.881 (95%CI=0.799~0.963, p-value=1.299e-6), accuracy=82.0%, 183 
sensitivity=86.7%, specificity=82.0%, PPV=44.8%, NPV=97.3%. The ROC 184 
curve of the full dataset was compared with those based on univariate models 185 
and the model from our previous study for RILT, as shown in Figure 4. 186 
 187 
Discussion 188 
In this study, we studied 30 cytokines from 131 NSCLC patients enrolled in 189 
prospective clinical trials. Although our initial hypothesis was the temporal 190 
change of cytokines during RT can predict RP2 better than baseline 191 
measurements alone, the results of this study demonstrated that the 192 
expression levels of two cytokines (IL-8 and CCL2) were statistically 193 
significant for RP2, while none of the rates in the change of cytokines was 194 
significant for RP2. This has an important meaning that the individual’s 195 
intrinsic micro-environment of patients, especially inflammation cytokine 196 
levels before RT, plays an important role in the following progress of RP2 in 197 
the patient with NSCLC underwent RT.  198 
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 199 
As described above previous groups15-21,28,29 have reported that biologic 200 
factors for RP prediction. In smaller datasets, TGF-β115, IL-616,17, IL-1A16, 201 
SOD18, GPX18 have shown significant p-values with RP.. Specifically, IL-6 and 202 
IL-1A had been studied for their prediction ability as reported sensitivities of 203 
50% and 53% respectively.16 Rs1982073 in TGF-β1, rs11466345 in TGF-β1 204 
and rs10898880 in ATG16L2 had hazard ratios (0.489, 2.2 and 1.8 205 
respectively). Other research groups4,30,31 used simple clinical variables to 206 
predicting the RP progression, such as MLD (odds ratio=2.02) and lung 207 
receiving 20 Gy of radiotherapy (odds ratio=1.41).  Notably, Valdes G et al.32 208 
used machine learning in predicting RP. They found radiation dosimetric 209 
parameters and patients’ race were important features in RUSBoost algorithm, 210 
however the accuracy of their classification is limited and the algorithm is 211 
difficult for a clinical usage. We compared them in details as shown in 212 
Supplementary Table S3. While in our study, we developed and validated a 213 
predictive model for RP2 with AUC=0.863, using stringent statistical method 214 
and machine learning approach. This GLM model included IL-8 and CCL2 at 215 
baseline level and two clinical variables (MLD and Hypertension) as early 216 
predictors of RP2. We also validated in the completely independent test-set, 217 
with the model predictive values of over 80% (AUC=0.863, Sensitivity=100%, 218 
Specificity=0.765%), numerically better than those previous reports for RP.  219 
 220 
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Furthermore, since it predicts RP2 based on cytokines at the baseline,  our 221 
model may provide an opportunity to personalize radiation treatment 222 
guidance before RT start. To our knowledge, this is the first study to validate 223 
that IL-8 and CCL2 as the early predictors for RP2, particularly to predict RP2 224 
before RT start. Using the nomogram in Figure 3, the risk of RP2 can be 225 
calculated based on the patient’s IL-8 and CCL2 levels, hypertension, and 226 
MLD values before RT start. Even the MLD value can be modulated to control 227 
the RP2 risk, which may contribute to patients’ overall survival. Therefore, 228 
predicting the risk of RP2 before RT may provide guidance for the 229 
aggressiveness of the RT treatment or prescribing anti-inflammation 230 
treatment.  231 
 232 
Our model is promising with a predictive accuracy of 0.86. The relatively high 233 
accuracy of our final GLM model may partially contribute to consideration of 234 
clinically important variables. MLD’s contribution in RP2 is consistent with 235 
previous literatures studied in RILT.7,8,10-12 Interestingly, hypertension was 236 
found that have the contribution to RP2. The biologic mechanism is unclear 237 
regarding the relationship between hypertension and RP2. It is possible that 238 
the progression of hypertension is associated with inflammation and fibrosis. 239 
However, whether inflammation is the cause or effect of hypertension is not 240 
well understood.33 Of additional note, the effect of Tumor Location on RP2 241 
was also tested here as it was previously reported in both patient34 and 242 
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animal studies.35,36 Although we considered it as a candidate predictor, tumor 243 
location parameter was not significant so as to be included in multivariate 244 
consideration, but not included in the final predictive GLM model. This result 245 
does not necessarily imply that tumor location is insignificant, since our 246 
sample included 20% tumor with unknown location. More so, this may be due 247 
to the fact that the majority of our patients were stage III with some 248 
component of central diseases.  249 
 250 
It is known that cytokines play an important role in RP2. In our study, lower IL-8 251 
level was found statistically significant with higher risk of RP2, which is 252 
consistent with previous literature on RILT. Both of our previous studies8,37 and 253 
Hart et al.38 had reported that low IL-8 was correlated with an increased risk of 254 
RILT. IL-8 has chemotactic activity for leukocytes and induces collagen 255 
synthesis and cell proliferation39 in animal studies, but it has been consistently 256 
found to have an anti-inflammatory effect in humans.12,37,38,40 Furthermore, it 257 
has been shown that neutrophils penetrate the injury site and perform the 258 
critical tasks of dismantling injured vessels and creating channels for new 259 
vascular regrowth, which is important for full repair of the sterile injury.41 This 260 
discovery strongly supported our results that higher level of IL-8 before RT was 261 
correlated with lower risk of RP. We believe that higher level of IL-8 can 262 
chemotaxis more neutrophils, to migrate toward the site of injury caused by 263 
radiation. As enough neutrophils be recruited and activated in the repair 264 
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process, the progress of RP will not be happened because the radiation injury 265 
was almost being repaired. 266 
 267 
This study is the first to demonstrate that low CCL2 level was associated with 268 
the increased risk of RP2. CCL2 was also known as involved in attracting 269 
neutrophils in animal studies. These factors may work together with IL-8 in RP 270 
process, as they are recognized in other conditions like inflammation of 271 
vascular disease. It may be reasonable to hypothesize that long-term 272 
overexpression of CCL2 in humans may play the same anti-inflammation role 273 
as IL-8. This needs to be validated and be a focus of future research.  274 
 275 
It is interesting to note that neither the rate of change in TGF-β1 during 276 
treatment nor the baseline level of TGF-β1 was significantly associated with 277 
RP2; and its’ AUC for RP2 on the dataset was 0.507, as shown in Figure 3. 278 
This was different from some previous studies that investigated plasma 279 
TGF-β1 as a predictor for RILT, including our own studies.8,11-13,15,20,22,37,42 280 
This controversial result may be multifactorial. Firstly, definitions of RP and 281 
RILT were not consistent as described in the introduction section, which may 282 
have confounded the results. The role of TGF-β1 may be more prominent for 283 
fibrosis.37,43 Secondly, TGF-β1 can be produced by both tumor and normal 284 
tissues, which seriously confound its role on RP2. The insignificant results of 285 
TGF-β1 on RP2 does not override its effect on RILF or RILT. Studies with 286 
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larger numbers of events or stratified analysis with consideration of TGF-β1 287 
effect on tumor are needed.  288 
 289 
While this study may be somewhat limited in the number of RP2 events and 290 
number of cytokines tested, this has been corrected by Bonferroni test, a 291 
stringent methodology for correction as well as by the use of machine 292 
learning algorithms, a stringent methodology for ensuring model’s 293 
generalization. Our study continues to show that inflammatory cytokines play 294 
an important role in the evolution of radiation pneumonitis and further clinical 295 
studies leveraging these relationships are warranted.   296 
 297 
In summary, this study demonstrated that two inflammatory cytokines (IL-8 298 
and CCL2) have strong correlation with RP2, while the temporal rate of 299 
cytokine levels had no statistical significance with RP2. According to machine 300 
learning algorithms, we established a predictive GLM model which included 301 
mean lung dose, hypertension and both IL-8 and CCL2 at baseline levels as 302 
early predictors of radiation pneumonitis. The predictive performance of the 303 
model was validated in the independent test-set with an AUC=0.863, 304 
Sensitivity=100%, and Specificity= 76.5%. This model and its nomogram, if 305 
further validated externally, can provide an opportunity of guiding 306 
personalized lung cancer treatment plan according to individual’s 307 
inflammatory cytokines.  308 
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Tables 
Table 1. Association between clinical variables and RP2 
Characteristic 
All patients 
n (%) 
Without RP2 
n (%) 
With RP2 
n (%) 
p-value 
Gender 
$
 
male 
female 
101 (77.1%) 
30 (22.9%) 
87 (76.3%) 
27 (23.7%) 
14 (82.4%) 
3 (17.6%) 
0.761 
Age 
#
 
Median 
1
st
 – 3
rd
 Qu 
65.7 
(59.4 – 73.9) 
65.7 
(59.4 – 73.5) 
66.01 
(60.1 - 77.2) 
0.911 
KPS 
#
 
Median 
1
st
 – 3
rd
 Qu 
90.0 
(80.0 - 90.0) 
90.0 
(80.0 - 90.0) 
90.0 
(85.0 - 90.0) 
0.328 
Smoking status 
$
 
Never 
Current/form
er 
6 (4.6%) 
125 (95.4%) 
5 (4.4%) 
109 (95.6%) 
1 (5.9%) 
16 (94.1%) 
0.573 
COPD 
&
 
No 
Yes 
72 (55.0%) 
59 (45.0%) 
62 (54.4%) 
52 (45.6%) 
10 (58.8%) 
7 (41.2%) 
0.935 
CVD 
&
 
No 
Yes 
86 (65.6%) 
45 (34.3%) 
77 (67.5%) 
37 (32.5%) 
9 (52.9%) 
8 (47.1%) 
0.363 
Hypertension 
$
 
No 
Yes 
61 (46.6%) 
70 (53.4%) 
57 (50.0%) 
57 (50.0%) 
4 (23.5%) 
13 (76.5%) 
0.066  
GTV (cm
3
)
 #
 
Median 
1
st
 – 3
rd
 Qu 
135.5 
(65.7 – 268.0) 
126.2 
(57.1 – 251.5) 
186.3 
(109.6 – 337.6) 
0.088  
Tumor location 
$
 
Central 
Peripheral 
Unknown 
80 (61.1%) 
23 (17.6%) 
28 (21.4%) 
67 (58.8%) 
22 (19.3%) 
25 (21.9%) 
13 (76.5%) 
1 (5.9%) 
3 (17.6%) 
0.380 
Clinical stage 
$
 
I 
II 
III 
15 (11.4%) 
12 (9.2%) 
104 (79.4%) 
13 (11.4%) 
11 (9.7%) 
90 (78.9%) 
2 (11.8%) 
1 (5.8%) 
14 (82.4%) 
1 
MLD (Gy) 
#
 
Median 
1
st
 – 3
rd
 Qu~ 
17.2 
(14.2 – 19.8) 
16.9 
(13.6 – 19.3) 
18.8 
(17.5 – 20.8) 
0.029 * 
MHD (%) 
#
 
Median 
1
st
 – 3
rd
 Qu~ 
11.3 
(4.5 – 19.1) 
10.8 
(4.3 – 18.6) 
16.9 
(9.6 – 19.8) 
0.194  
EQD2 (Gy) 
#
 
Median 
1
st
 – 3
rd
 Qu~ 
70.0 
(65.0 - 78.0) 
70.0 
(65.0 - 77.9) 
76.2 
(65.0 - 81.9) 
0.308 
Chemotherapy 
$
 
No 
Yes 
20 (15.3%) 
111 (84.7%) 
17 (14.9%) 
97 (85.1%) 
3 (17.6%) 
14 (82.4%) 
0.724 
Abbreviation: KPS = Karnofsky Performance Status; COPD = Chronic obstructive pulmonary disease; 
CVD = Cardiovascular disease; GTV = gross tumor volume; MLD = mean lung dose; MHD = mean heart 
dose; EQD2 = equivalent dose in 2 Gy fractions;  
$ Fisher’s exact test; & Chi-square test; # logistic regression; ~QU=quartile 
* p-value < 0.05;  < 0.1 
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Table 2. Single cytokines’ level and the final GLM model for predicting risk RP2 
variables 
Estimate 
coefficient 
Standard 
error 
Odds ratio 
#
 
confidence 
interval 
95% 
p-value 
Single 
Cytokines 
IL-8 -1.177 0.281 0.308 0.178 – 0.535 2.8e-5 ** 
CCL2 -0.979 0.295 0.376 0.211 – 0.669 8.9e-4 ** 
The final 
GLM 
model 
(Intercept) -0.569 3.038 0.566 0.001 – 226.743 0.851 
IL-8 -0.887 0.371 0.412 0.183 – 0.810 0.017 * 
CCL2 -1.190 0.471 0.304 0.107 – 0.734 0.011 * 
Hypertension 1.993 1.086 7.337 1.128 – 90.945 0.066 
MLD 0.321 0.161 1.378 1.058 – 2.017 0.046 * 
#
 Ratio of levels in patient with RP2 / without RP2 
* p-value < 0.05; ** < 0.0017 (Bonferroni) 
 
 
Figure Legends 
Figure 1. Temporal data of cytokine expression levels: (left) IL-8, (right) CCL2 (means ± 
95% confidence interval) 
 
Figure 2. Visualization of the continuous predicting candidates’ distribution and correlation. 
Corr= Pearson Correlation Coefficient. (x- and y-coordinate are predictors’ level).  
 
Figure 3. The nomogram for risk RP2, constructed based on the final GLM model. It based on 
two cytokines (IL-8 and CCL2) and two clinical variables (Hypertension, MLD).  
 
Figure 4. ROC curves for risk RP2 on the whole dataset, comparing the final GLM model with 
single cytokines (IL-8, CCL2, TGF-β1); and comparing with IL-8+TGF-β1+MLD, which were 
referenced from our previous study for predicting RILT.
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